Published in Respiration on November 20, 2007
The cancer paradigm of severe pulmonary arterial hypertension. Am J Respir Crit Care Med (2008) 3.09
Basic science of pulmonary arterial hypertension for clinicians: new concepts and experimental therapies. Circulation (2010) 2.85
Relevant issues in the pathology and pathobiology of pulmonary hypertension. J Am Coll Cardiol (2013) 1.96
Regulatory T cells limit vascular endothelial injury and prevent pulmonary hypertension. Circ Res (2011) 1.31
Regulatory T cells in cardiovascular diseases. Nat Rev Cardiol (2015) 1.04
STAT3 signaling in pulmonary arterial hypertension. JAKSTAT (2012) 1.04
Immune and inflammatory mechanisms in pulmonary arterial hypertension. Prog Cardiovasc Dis (2012) 1.03
T lymphocyte subset abnormalities in the blood and lung in pulmonary arterial hypertension. Respir Med (2009) 0.98
Association between circulating specific leukocyte types and blood pressure: the atherosclerosis risk in communities (ARIC) study. J Am Soc Hypertens (2010) 0.89
Circulating myeloid-derived suppressor cells are increased and activated in pulmonary hypertension. Chest (2011) 0.84
Perivascular T-cell infiltration leads to sustained pulmonary artery remodeling after endothelial cell damage. Am J Respir Cell Mol Biol (2010) 0.82
Regulatory T cells and pulmonary hypertension. Trends Cardiovasc Med (2011) 0.79
Complement components as potential therapeutic targets for asthma treatment. Respir Med (2014) 0.79
Understanding the role of CD4+CD25(high) (so-called regulatory) T cells in idiopathic pulmonary arterial hypertension. Respiration (2008) 0.77
Comparative Transcriptome Analysis Identifies CCDC80 as a Novel Gene Associated with Pulmonary Arterial Hypertension. Front Pharmacol (2016) 0.77
The sexual dimorphism associated with pulmonary hypertension corresponds to a fibrotic phenotype. Pulm Circ (2015) 0.77
Non-suppressive regulatory T cell subset expansion in pulmonary arterial hypertension. Heart Vessels (2015) 0.76
Acute effects of exercise on the inflammatory state in patients with idiopathic pulmonary arterial hypertension. BMC Pulm Med (2016) 0.75
Control of regulatory T cell development by the transcription factor Foxp3. Science (2003) 40.32
Foxp3 programs the development and function of CD4+CD25+ regulatory T cells. Nat Immunol (2003) 38.57
Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J Immunol (1995) 29.42
Restoring function in exhausted CD8 T cells during chronic viral infection. Nature (2005) 28.04
Naturally arising CD4+ regulatory t cells for immunologic self-tolerance and negative control of immune responses. Annu Rev Immunol (2004) 17.40
Regulatory T cells: key controllers of immunologic self-tolerance. Cell (2000) 10.19
Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med (2005) 9.27
The three Es of cancer immunoediting. Annu Rev Immunol (2004) 8.20
Molecular and functional profiling of memory CD8 T cell differentiation. Cell (2002) 8.06
Heterozygous germline mutations in BMPR2, encoding a TGF-beta receptor, cause familial primary pulmonary hypertension. Nat Genet (2000) 7.20
Induction of interleukin 10-producing, nonproliferating CD4(+) T cells with regulatory properties by repetitive stimulation with allogeneic immature human dendritic cells. J Exp Med (2000) 6.45
Induction of FoxP3 and acquisition of T regulatory activity by stimulated human CD4+CD25- T cells. J Clin Invest (2003) 6.42
Clinical classification of pulmonary hypertension. J Am Coll Cardiol (2004) 5.87
Cellular and molecular pathobiology of pulmonary arterial hypertension. J Am Coll Cardiol (2004) 5.79
Induction of tolerance by IL-10-treated dendritic cells. J Immunol (1997) 4.65
T cells and viral persistence: lessons from diverse infections. Nat Immunol (2005) 4.12
Exuberant endothelial cell growth and elements of inflammation are present in plexiform lesions of pulmonary hypertension. Am J Pathol (1994) 3.83
Increase of regulatory T cells in the peripheral blood of cancer patients. Clin Cancer Res (2003) 3.44
Certified professionals: CD4(+)CD25(+) suppressor T cells. J Exp Med (2001) 3.39
Characterization of CD4+CD25+ regulatory T cells in patients treated with high-dose interleukin-2 for metastatic melanoma or renal cell carcinoma. J Clin Oncol (2006) 3.28
Inhibition of the VEGF receptor 2 combined with chronic hypoxia causes cell death-dependent pulmonary endothelial cell proliferation and severe pulmonary hypertension. FASEB J (2001) 3.20
Inflammation in pulmonary arterial hypertension. Eur Respir J (2003) 3.18
Expression of human herpesvirus 8 in primary pulmonary hypertension. N Engl J Med (2003) 3.00
Autoimmunity and pulmonary hypertension: a perspective. Eur Respir J (2005) 2.82
Sporadic primary pulmonary hypertension is associated with germline mutations of the gene encoding BMPR-II, a receptor member of the TGF-beta family. J Med Genet (2000) 2.82
Quantification of regulatory T cells in patients with systemic lupus erythematosus. J Autoimmun (2003) 2.81
Increased populations of regulatory T cells in peripheral blood of patients with hepatocellular carcinoma. Cancer Res (2005) 2.78
Cutting edge: human CD4+CD25+ T cells restrain the maturation and antigen-presenting function of dendritic cells. J Immunol (2004) 2.56
Primary pulmonary hypertension in HIV infection. Chest (1991) 2.40
Dendritic cells as a tool to induce anergic and regulatory T cells. Trends Immunol (2001) 2.20
Tumor-specific shared antigenic peptides recognized by human T cells. Immunol Rev (2002) 2.18
Low CD8 T-cell proliferative potential and high viral load limit the effectiveness of therapeutic vaccination. J Virol (2005) 2.06
The regulatory T cell family: distinct subsets and their interrelations. J Immunol (2003) 1.92
Decreased CD4+CD25+ T cells in peripheral blood of patients with systemic lupus erythematosus. Scand J Immunol (2004) 1.92
Measurement and characterisation of circulating anti-endothelial cell IgG in connective tissue diseases. Clin Exp Immunol (1988) 1.83
Dendritic cell recruitment in lesions of human and experimental pulmonary hypertension. Eur Respir J (2006) 1.78
Relationship of CD4+CD25+ regulatory T cells to immune status in HIV-infected patients. AIDS (2005) 1.76
Immunoregulatory T cells in tumor immunity. Curr Opin Immunol (2004) 1.69
Increase of CD4+ CD25+ regulatory T-cells in the liver of patients with hepatocellular carcinoma. J Hepatol (2006) 1.60
Modulation of the CD8+-T-cell response by CD4+ CD25+ regulatory T cells in patients with hepatitis B virus infection. J Virol (2005) 1.60
Regulatory T cells in immunologic self-tolerance and autoimmune disease. Int Rev Immunol (2005) 1.57
Primary pulmonary hypertension between inflammation and cancer. Chest (1998) 1.57
Pulmonary hypertension in the CREST syndrome variant of progressive systemic sclerosis (scleroderma). Ann Intern Med (1977) 1.57
Genetic basis of pulmonary arterial hypertension: current understanding and future directions. J Am Coll Cardiol (2004) 1.53
Absence of T cells confers increased pulmonary arterial hypertension and vascular remodeling. Am J Respir Crit Care Med (2007) 1.42
Lymphocyte subsets' reference ranges in an age- and gender-balanced population of 100 healthy adults--a monocentric German study. Clin Immunol (2005) 1.42
CD4+CD25+ regulatory T-cell deficiency in patients with hepatitis C-mixed cryoglobulinemia vasculitis. Blood (2003) 1.41
HIV-associated primary pulmonary hypertension. A case control study. Swiss HIV Cohort Study. Am J Respir Crit Care Med (1997) 1.35
Pulmonary hypertension in systemic sclerosis: risk factors for progression and consequences for survival. Rheumatology (Oxford) (2001) 1.35
The pathobiology of pulmonary hypertension. Endothelium. Clin Chest Med (2001) 1.27
Prostanoid therapy for pulmonary arterial hypertension. J Am Coll Cardiol (2004) 1.22
Pulmonary hypertension associated with connective tissue disease. Prog Cardiovasc Dis (2003) 1.21
Effect of medical castration on CD4+ CD25+ T cells, CD8+ T cell IFN-gamma expression, and NK cells: a physiological role for testosterone and/or its metabolites. Am J Physiol Endocrinol Metab (2005) 1.21
Endothelin receptor antagonists in pulmonary arterial hypertension. J Am Coll Cardiol (2004) 1.19
Cellular and molecular mechanisms in the pathogenesis of severe pulmonary hypertension. Eur Respir J (1995) 1.17
Enrichment of CD4+ CD25high T cell population in patients with systemic lupus erythematosus treated with glucocorticoids. Ann Rheum Dis (2006) 1.17
Dynamic regulation of FoxP3 expression controls the balance between CD4+ T cell activation and cell death. Eur J Immunol (2005) 1.14
Tolerogenic dendritic cells and regulatory T cells: a two-way relationship. J Dermatol Sci (2007) 1.14
Reduced expression of the regulatory CD4+ T cell subset is related to Th1/Th2 balance and disease severity in rheumatoid arthritis. Arthritis Rheum (2000) 1.12
Prevalence of pulmonary hypertension in limited and diffuse scleroderma. Chest (1996) 1.09
Genes and pulmonary arterial hypertension. Respiration (2007) 1.08
Antiendothelial cell antibodies in scleroderma correlate with severe digital ischemia and pulmonary arterial hypertension. J Rheumatol (1998) 1.08
Anti-endothelial cell antibodies in idiopathic and systemic sclerosis associated pulmonary arterial hypertension. Thorax (2005) 1.03
Lung mast cells in plexogenic pulmonary arteriopathy. J Clin Pathol (1991) 1.03
Isolated pulmonary hypertension in systemic sclerosis with diffuse cutaneous involvement: association with serum anti-U3RNP antibody. J Rheumatol (1996) 1.03
Immunologic self tolerance maintained by T-cell-mediated control of self-reactive T cells: implications for autoimmunity and tumor immunity. Microbes Infect (2001) 1.00
Pathology of pulmonary hypertension. Cardiol Clin (2004) 0.99
Angiogenesis and pulmonary hypertension: a unique process in a unique disease. Antioxid Redox Signal (2002) 0.98
Antibodies to fibroblasts in idiopathic and scleroderma-associated pulmonary hypertension. Eur Respir J (2006) 0.97
Evidence for vascular remodeling in the lungs of macaques infected with simian immunodeficiency virus/HIV NEF recombinant virus. Chest (2005) 0.96
A role for regulatory T cells in cutaneous T-Cell lymphoma; induction of a CD4 + CD25 + Foxp3+ T-cell phenotype associated with HTLV-1 infection. J Invest Dermatol (2006) 0.95
Pulmonary hypertension in autoimmune rheumatic diseases. Autoimmun Rev (2004) 0.89
Pulmonary hypertension in autoimmune rheumatic diseases: where are we now? Arthritis Rheum (2002) 0.88
Mutations of bone morphogenetic protein receptor type II are not found in patients with pulmonary hypertension and underlying connective tissue diseases. Arthritis Rheum (2002) 0.86
The Janus face of CD4+CD25+ regulatory T cells in cancer and autoimmunity. Curr Med Chem (2007) 0.85
Infliximab treatment in a patient with systemic sclerosis associated with lung fibrosis and pulmonary hypertension. Respiration (2005) 0.85
The protective role of T-lymphocytes in pulmonary vascular remodeling. Chest (2005) 0.84
Autoimmune disease and unexplained pulmonary hypertension. Circulation (1992) 0.83
Pulmonary hypertension in systemic autoimmune disease. Rheum Dis Clin North Am (1997) 0.83
Autoimmune aspects of primary pulmonary hypertension. Pathobiology (1995) 0.79
The role of regulatory T cell defects in type I diabetes and the potential of these cells for therapy. Rev Diabet Stud (2005) 0.79
Absence of human herpesvirus 8 DNA sequences in lung biopsies from Israeli patients with pulmonary arterial hypertension. Respiration (2006) 0.79
Immunologic tolerance maintained by regulatory T cells: implications for autoimmunity, tumor immunity and transplantation tolerance. Vox Sang (2002) 0.78
The assessment of anti-endothelial cell antibodies in scleroderma-associated pulmonary fibrosis. A study of indirect immunofluorescent and western blot analysis in 49 patients with scleroderma. Am J Clin Pathol (2003) 0.78
Autoimmune aspects of pulmonary hypertension in collagen vascular diseases. Intern Med (2003) 0.76
Clinical classification of pulmonary hypertension. J Am Coll Cardiol (2004) 5.87
Inhaled iloprost for severe pulmonary hypertension. N Engl J Med (2002) 3.90
Anticoagulation and survival in pulmonary arterial hypertension: results from the Comparative, Prospective Registry of Newly Initiated Therapies for Pulmonary Hypertension (COMPERA). Circulation (2013) 3.90
Temporal response of the human virome to immunosuppression and antiviral therapy. Cell (2013) 2.72
Interleukin-6 modulates the expression of the bone morphogenic protein receptor type II through a novel STAT3-microRNA cluster 17/92 pathway. Circ Res (2009) 2.61
An animal model of autoimmune emphysema. Am J Respir Crit Care Med (2004) 2.40
Characterization of connective tissue disease-associated pulmonary arterial hypertension from REVEAL: identifying systemic sclerosis as a unique phenotype. Chest (2010) 2.35
Comparison of mycophenolate mofetil and azathioprine for prevention of bronchiolitis obliterans syndrome in de novo lung transplant recipients. Transplantation (2006) 2.07
Chronic thromboembolic pulmonary hypertension (CTEPH): results from an international prospective registry. Circulation (2011) 1.92
Pulmonary arterial hypertension related to HIV infection: improved hemodynamics and survival associated with antiretroviral therapy. Clin Infect Dis (2004) 1.89
Safety and efficacy of exercise training in various forms of pulmonary hypertension. Eur Respir J (2012) 1.83
Lung transplant airway hypoxia: a diathesis to fibrosis? Am J Respir Crit Care Med (2010) 1.77
Inhibiting lung elastase activity enables lung growth in mechanically ventilated newborn mice. Am J Respir Crit Care Med (2011) 1.67
Increased resource use in lung transplant admissions in the lung allocation score era. Am J Respir Crit Care Med (2015) 1.45
Absence of T cells confers increased pulmonary arterial hypertension and vascular remodeling. Am J Respir Crit Care Med (2007) 1.42
Bosentan for the treatment of human immunodeficiency virus-associated pulmonary arterial hypertension. Am J Respir Crit Care Med (2004) 1.40
Pathobiology of pulmonary arterial hypertension and right ventricular failure. Eur Respir J (2012) 1.39
Microvascular destruction identifies murine allografts that cannot be rescued from airway fibrosis. J Clin Invest (2007) 1.38
Adenovirus-mediated HIF-1α gene transfer promotes repair of mouse airway allograft microvasculature and attenuates chronic rejection. J Clin Invest (2011) 1.35
Endogenous signals released from necrotic cells augment inflammatory responses to bacterial endotoxin. Immunol Lett (2007) 1.35
Regulatory T cells limit vascular endothelial injury and prevent pulmonary hypertension. Circ Res (2011) 1.31
Identification of novel resident pulmonary stem cells: form and function of the lung side population. Stem Cells (2005) 1.27
Alpha-1 antitrypsin inhibits caspase-1 and protects from acute myocardial ischemia-reperfusion injury. J Mol Cell Cardiol (2011) 1.23
Simultaneous LFA-1 and CD40 ligand antagonism prevents airway remodeling in orthotopic airway transplantation: implications for the role of respiratory epithelium as a modulator of fibrosis. J Immunol (2005) 1.18
Anti-inflammatory effect of thymoquinone in a mouse model of allergic lung inflammation. Int Immunopharmacol (2006) 1.18
A brief overview of mouse models of pulmonary arterial hypertension: problems and prospects. Am J Physiol Lung Cell Mol Physiol (2012) 1.18
Heterogeneity of barrier function in the lung reflects diversity in endothelial cell junctions. Microvasc Res (2007) 1.13
Reference values for the 6-minute walk test in healthy children and adolescents in Switzerland. BMC Pulm Med (2013) 1.12
Clinical features of gamma-hydroxybutyrate and gamma-butyrolactone toxicity and concomitant drug and alcohol use. Drug Alcohol Depend (2005) 1.09
Strategic plan for lung vascular research: An NHLBI-ORDR Workshop Report. Am J Respir Crit Care Med (2010) 1.09
MicroRNA-18a enhances the interleukin-6-mediated production of the acute-phase proteins fibrinogen and haptoglobin in human hepatocytes. J Biol Chem (2011) 1.09
Expression and function of EZH2 in synovial fibroblasts: epigenetic repression of the Wnt inhibitor SFRP1 in rheumatoid arthritis. Ann Rheum Dis (2011) 1.08
Type 2 diabetes mellitus as a conformational disease. JOP (2005) 1.06
Blocking macrophage leukotriene b4 prevents endothelial injury and reverses pulmonary hypertension. Sci Transl Med (2013) 1.05
Elafin Reverses Pulmonary Hypertension via Caveolin-1-Dependent Bone Morphogenetic Protein Signaling. Am J Respir Crit Care Med (2015) 1.04
Inflammatory cytokines in pulmonary hypertension. Respir Res (2014) 1.03
Ganciclovir/valganciclovir prophylaxis decreases cytomegalovirus-related events and bronchiolitis obliterans syndrome after lung transplantation. Clin Infect Dis (2008) 1.03
Lung transplantation for lymphangioleiomyomatosis: the European experience. J Heart Lung Transplant (2009) 1.03
Osteoporosis before lung transplantation: association with low body mass index, but not with underlying disease. Am J Transplant (2002) 1.02
Peripheral blood B lymphocytes derived from patients with idiopathic pulmonary arterial hypertension express a different RNA pattern compared with healthy controls: a cross sectional study. Respir Res (2008) 0.99
Following universal prophylaxis with intravenous ganciclovir and cytomegalovirus immune globulin, valganciclovir is safe and effective for prevention of CMV infection following lung transplantation. Am J Transplant (2004) 0.99
Human infection with Delftia tsuruhatensis isolated from a central venous catheter. J Med Microbiol (2010) 0.97
Effect of thymoquinone on cyclooxygenase expression and prostaglandin production in a mouse model of allergic airway inflammation. Immunol Lett (2006) 0.96
Evidence for vascular remodeling in the lungs of macaques infected with simian immunodeficiency virus/HIV NEF recombinant virus. Chest (2005) 0.96
Unique predictors of mortality in patients with pulmonary arterial hypertension associated with systemic sclerosis in the REVEAL registry. Chest (2014) 0.96
Daytime measurements underestimate nocturnal oxygen desaturations in pulmonary arterial and chronic thromboembolic pulmonary hypertension. Respiration (2012) 0.94
CD4+ T cells and complement independently mediate graft ischemia in the rejection of mouse orthotopic tracheal transplants. Circ Res (2011) 0.94
Neonatal mice genetically modified to express the elastase inhibitor elafin are protected against the adverse effects of mechanical ventilation on lung growth. Am J Physiol Lung Cell Mol Physiol (2012) 0.94
Sleep-related breathing disorders in patients with pulmonary hypertension. Chest (2008) 0.94
Is alveolar destruction and emphysema in chronic obstructive pulmonary disease an immune disease? Proc Am Thorac Soc (2006) 0.92
Tobacco smoke: a risk factor for pulmonary arterial hypertension? A case-control study. Chest (2010) 0.92
Severe pulmonary arterial hypertension induced by SU5416 and ovalbumin immunization. Am J Respir Cell Mol Biol (2012) 0.92
Thymoquinone attenuates proinflammatory responses in lipopolysaccharide-activated mast cells by modulating NF-kappaB nuclear transactivation. Biochim Biophys Acta (2007) 0.91
Targeting complement component 5a promotes vascular integrity and limits airway remodeling. Proc Natl Acad Sci U S A (2013) 0.90
Genetic polymorphisms of the serotonin transporter, but not the 2a receptor or nitric oxide synthetase, are associated with pulmonary hypertension in chronic obstructive pulmonary disease. Respiration (2009) 0.88
Massive dilatation of the pulmonary artery in association with pulmonic stenosis and pulmonary hypertension. Pulm Circ (2012) 0.88
Gene microarray study corroborates proteomic findings in rodent islet cells. J Proteome Res (2003) 0.88
Graft microvascular disease in solid organ transplantation. J Mol Med (Berl) (2014) 0.88
Pulmonary hypertension in Switzerland: treatment and clinical course. Swiss Med Wkly (2008) 0.87
Chronic thromboembolic and pulmonary arterial hypertension share acute vasoreactivity properties. Chest (2006) 0.87
Pulmonary capillary hemangiomatosis: an immunohistochemical analysis of vascular remodeling in a fatal case. Chest (2005) 0.86
The critical role of mRNA destabilizing protein heterogeneous nuclear ribonucleoprotein d in 3' untranslated region-mediated decay of low-density lipoprotein receptor mRNA in liver tissue. Arterioscler Thromb Vasc Biol (2013) 0.86
New methods for monitoring dynamic airway tissue oxygenation and perfusion in experimental and clinical transplantation. Am J Physiol Lung Cell Mol Physiol (2012) 0.86
Efficacy of exercise training in pulmonary arterial hypertension associated with congenital heart disease. Int J Cardiol (2012) 0.86
Downregulation of leukotriene biosynthesis by thymoquinone attenuates airway inflammation in a mouse model of allergic asthma. Biochim Biophys Acta (2006) 0.85
Complement-mediated microvascular injury leads to chronic rejection. Adv Exp Med Biol (2013) 0.85
Mechanisms of autoimmune emphysema. Proc Am Thorac Soc (2006) 0.85
Not all intravenous immunoglobulin preparations are equally well tolerated. Acta Derm Venereol (2010) 0.85
A mouse model of radiation-induced cardiomyopathy. Int J Cardiol (2012) 0.85
True survival benefit of lung transplantation for cystic fibrosis patients: the Zurich experience. J Heart Lung Transplant (2009) 0.84
The protective role of T-lymphocytes in pulmonary vascular remodeling. Chest (2005) 0.84
Inhibition of apoptosis signal-regulating kinase 1 reduces myocardial ischemia-reperfusion injury in the mouse. J Am Heart Assoc (2012) 0.84
Pulmonary hypertension due to left heart disease: updated Recommendations of the Cologne Consensus Conference 2011. Int J Cardiol (2011) 0.83
The German adaptation of the Cambridge Pulmonary Hypertension Outcome Review (CAMPHOR). Health Qual Life Outcomes (2012) 0.83
Lung-volume reduction surgery as an alternative or bridging procedure to lung transplantation. Ann Thorac Surg (2006) 0.83
Extended donor lungs: eleven years experience in a consecutive series. Eur J Cardiothorac Surg (2005) 0.83
Extracorporeal photopheresis after lung transplantation: a 10-year single-center experience. Transplantation (2008) 0.82
Nuclear factor κB inhibition reduces lung vascular lumen obliteration in severe pulmonary hypertension in rats. Am J Respir Cell Mol Biol (2014) 0.82
Transforming growth factor-β1 rise in pleural fluid after tunneled pleural catheter placement: pilot study. J Bronchology Interv Pulmonol (2013) 0.82
Chemokine-mediated angiogenesis: an essential link in the evolution of airway fibrosis? J Clin Invest (2005) 0.82
Effects of sinus surgery in patients with cystic fibrosis after lung transplantation: a 10-year experience. Transplantation (2004) 0.81
A low resting heart rate at diagnosis predicts favourable long-term outcome in pulmonary arterial and chronic thromboembolic pulmonary hypertension. A prospective observational study. Respir Res (2012) 0.81
Altered oxido-reductive state in the diabetic heart: loss of cardioprotection due to protein disulfide isomerase. Mol Med (2011) 0.81
Central venous catheter infections in outpatients with pulmonary hypertension treated with continuous iloprost. Respiration (2013) 0.81
Tie2-dependent VHL knockdown promotes airway microvascular regeneration and attenuates invasive growth of Aspergillus fumigatus. J Mol Med (Berl) (2013) 0.81
Leukotrienes in pulmonary arterial hypertension. Immunol Res (2014) 0.79
Macrophages in solid organ transplantation. Vasc Cell (2014) 0.79
Inflammation patterns in allogeneic and autologous airway tissue of lung transplant recipients. Am J Transplant (2005) 0.79
Diabetes mellitus and survival in cystic fibrosis patients after lung transplantation. J Cyst Fibros (2011) 0.79
Olfactory performance before and after lung transplantation: quantitative assessment and impact on quality of life. J Heart Lung Transplant (2009) 0.79
Tobacco smoke exposure in pulmonary arterial and thromboembolic pulmonary hypertension. Respiration (2014) 0.79
Regulatory T cells and pulmonary hypertension. Trends Cardiovasc Med (2011) 0.79
Caveolin-1 Expression and Hemodynamics in COPD Patients. Open Respir Med J (2009) 0.79
Pretransplantation bone disease in patients with primary pulmonary hypertension. Chest (2006) 0.79
Efficacy of transthoracic echocardiography for diagnosing heart failure in septic shock. Am J Med Sci (2014) 0.78
Transfer of allograft specific tolerance requires CD4+CD25+T cells but not interleukin-4 or transforming growth factor-beta and cannot induce tolerance to linked antigens. Transplantation (2007) 0.78
Bone mineral density and secondary hyperparathyroidism in pulmonary hypertension. Open Respir Med J (2009) 0.78